IL318651A - Ip5-substituted compounds - Google Patents
Ip5-substituted compoundsInfo
- Publication number
- IL318651A IL318651A IL318651A IL31865125A IL318651A IL 318651 A IL318651 A IL 318651A IL 318651 A IL318651 A IL 318651A IL 31865125 A IL31865125 A IL 31865125A IL 318651 A IL318651 A IL 318651A
- Authority
- IL
- Israel
- Prior art keywords
- substituted compounds
- substituted
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C35/02—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic
- C07C35/08—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic containing a six-membered rings
- C07C35/14—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic containing a six-membered rings with more than one hydroxy group bound to the ring
- C07C35/16—Inositols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/18—Ethers having an ether-oxygen atom bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C43/188—Unsaturated ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/18—Ethers having an ether-oxygen atom bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C43/196—Ethers having an ether-oxygen atom bound to a carbon atom of a ring other than a six-membered aromatic ring containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D201/00—Preparation, separation, purification or stabilisation of unsubstituted lactams
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
- C07F9/6518—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/6574—Esters of oxyacids of phosphorus
- C07F9/65744—Esters of oxyacids of phosphorus condensed with carbocyclic or heterocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22382737 | 2022-07-29 | ||
| PCT/EP2023/071141 WO2024023360A1 (en) | 2022-07-29 | 2023-07-31 | Ip5 substituted compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL318651A true IL318651A (en) | 2025-03-01 |
Family
ID=83319363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL318651A IL318651A (en) | 2022-07-29 | 2023-07-31 | Ip5-substituted compounds |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP4562019A1 (enExample) |
| JP (1) | JP2025525098A (enExample) |
| KR (1) | KR20250049546A (enExample) |
| CN (1) | CN119630679A (enExample) |
| AR (1) | AR130072A1 (enExample) |
| AU (1) | AU2023313051A1 (enExample) |
| CA (1) | CA3263493A1 (enExample) |
| IL (1) | IL318651A (enExample) |
| MX (1) | MX2025001128A (enExample) |
| TW (1) | TW202412815A (enExample) |
| WO (1) | WO2024023360A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025162971A1 (en) * | 2024-01-31 | 2025-08-07 | Sanifit Therapeutics, S.A. | Substituted ip5 compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5007790A (en) | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
| CA2132012C (en) | 1992-03-25 | 2003-04-22 | John W. Shell | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
| US5582837A (en) | 1992-03-25 | 1996-12-10 | Depomed, Inc. | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
| AU3290397A (en) | 1996-06-10 | 1998-01-07 | Depomed, Inc. | Gastric-retentive oral controlled drug delivery system with enhanced retention properties |
| US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
| ATE302597T1 (de) | 1997-06-06 | 2005-09-15 | Depomed Inc | Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung |
| US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
| NZ518739A (en) | 1999-11-02 | 2004-12-24 | Depomed Inc | Pharmacological inducement of the fed mode for enhanced drug administration to the stomach |
| MXPA02007254A (es) | 2000-02-04 | 2002-12-09 | Depomed Inc | Forma de dosis de cubierta-y-nucleo que se aproxima a liberacion de droga de orden cero. |
| US6488962B1 (en) | 2000-06-20 | 2002-12-03 | Depomed, Inc. | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
| US6451808B1 (en) | 2000-10-17 | 2002-09-17 | Depomed, Inc. | Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists |
| WO2002096404A1 (en) | 2001-05-29 | 2002-12-05 | Depomed Development Ltd | Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough |
| US20030091630A1 (en) | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
| JP2005508358A (ja) | 2001-10-25 | 2005-03-31 | デポメド・インコーポレイテッド | 胃滞留型ロサルタン投与量を用いる治療方法 |
| CA2409552A1 (en) | 2001-10-25 | 2003-04-25 | Depomed, Inc. | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
| US6682759B2 (en) | 2002-02-01 | 2004-01-27 | Depomed, Inc. | Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs |
| ES2232302B1 (es) | 2003-11-07 | 2006-08-01 | Universitat De Les Illes Balears | Myo-inositol hexafosfato para uso topico. |
| US7741506B2 (en) | 2005-04-26 | 2010-06-22 | Berry & Associates, Inc. | Probe for measuring phytase activity |
| US20060241308A1 (en) * | 2005-04-26 | 2006-10-26 | Berry & Associates, Inc. | Probe for measuring phytase activity |
| ES2288126B2 (es) | 2006-06-01 | 2009-07-06 | Universitat De Les Illes Balears | Utilizacion de fitato como agente inhibidor de la disolucion de cristales de sales calcicas para la prevencion o tratamiento de la osteoporosis. |
| ES2332636B1 (es) | 2008-08-06 | 2011-02-10 | Universitat De Les Illes Balears | Composicion de liquido de dialisis. |
| US8987514B2 (en) * | 2009-02-04 | 2015-03-24 | President And Fellows Of Harvard College | Compositions and methods for labeling and imaging phospholipids |
| GB0920985D0 (en) | 2009-11-30 | 2010-01-13 | Queen Mary & Westfield College | Novel inositol phosphate derivatives |
| EP2579036A1 (en) | 2011-10-06 | 2013-04-10 | Laboratorios Sanifit, S.L. | Method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200 |
| SMT202100406T1 (it) | 2015-12-11 | 2021-09-14 | Eth Zuerich | Derivati di inositolo per l'uso nella cristallizzazione patologica |
| EP3852767B1 (en) | 2018-09-18 | 2025-12-17 | Vifor (International) AG | Calcium oxalate crystallization inhibitors for renal disorders |
| WO2021219135A1 (zh) | 2020-04-30 | 2021-11-04 | 上海森辉医药有限公司 | 一种肌醇衍生物及其用途 |
| EP4036097A1 (en) * | 2021-01-29 | 2022-08-03 | Sanifit Therapeutics S.A. | Ip4-4,6 substituted derivative compounds |
-
2023
- 2023-07-28 TW TW112128482A patent/TW202412815A/zh unknown
- 2023-07-31 AU AU2023313051A patent/AU2023313051A1/en active Pending
- 2023-07-31 CA CA3263493A patent/CA3263493A1/en active Pending
- 2023-07-31 CN CN202380056920.2A patent/CN119630679A/zh active Pending
- 2023-07-31 EP EP23750984.9A patent/EP4562019A1/en active Pending
- 2023-07-31 JP JP2025505402A patent/JP2025525098A/ja active Pending
- 2023-07-31 IL IL318651A patent/IL318651A/en unknown
- 2023-07-31 AR ARP230102006A patent/AR130072A1/es unknown
- 2023-07-31 KR KR1020257006598A patent/KR20250049546A/ko active Pending
- 2023-07-31 WO PCT/EP2023/071141 patent/WO2024023360A1/en not_active Ceased
-
2025
- 2025-01-27 MX MX2025001128A patent/MX2025001128A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20250049546A (ko) | 2025-04-11 |
| EP4562019A1 (en) | 2025-06-04 |
| MX2025001128A (es) | 2025-03-07 |
| TW202412815A (zh) | 2024-04-01 |
| CN119630679A (zh) | 2025-03-14 |
| CA3263493A1 (en) | 2024-02-01 |
| AR130072A1 (es) | 2024-10-30 |
| JP2025525098A (ja) | 2025-08-01 |
| WO2024023360A1 (en) | 2024-02-01 |
| AU2023313051A1 (en) | 2025-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB202200735D0 (en) | Compounds | |
| GB202208643D0 (en) | Compounds | |
| GB202208151D0 (en) | Compounds | |
| CA3263493A1 (en) | COMPOUNDS SUBSTITUTED BY IP5 | |
| GB202300021D0 (en) | Compounds | |
| GB202214796D0 (en) | Compounds | |
| GB202208649D0 (en) | Antimirobial compounds | |
| GB202201996D0 (en) | Compounds | |
| GB2636825B (en) | Compounds | |
| GB202315830D0 (en) | Compounds | |
| GB202315014D0 (en) | Compounds | |
| GB202313594D0 (en) | Compounds | |
| GB202312738D0 (en) | Compounds | |
| GB202309882D0 (en) | Compounds | |
| GB202303387D0 (en) | Compounds | |
| GB202303230D0 (en) | Compounds | |
| GB202302237D0 (en) | Tryptophan-based compounds | |
| GB202300995D0 (en) | Compounds | |
| GB202300922D0 (en) | Compounds | |
| GB202219706D0 (en) | Compounds | |
| GB202219534D0 (en) | Compounds | |
| GB202217844D0 (en) | Compounds | |
| GB202217330D0 (en) | Compounds | |
| GB202216695D0 (en) | Compounds | |
| GB202215664D0 (en) | Compounds |